Then we are now focusing on pharmaceutical partnerships and are getting a good reception in that area I would say. We're also focusing on our own internal protein therapeutic program. So we have more resources now to push our own material ahead very aggressively. So the model for us is to generat...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
